I believe one of the best ways to generate market-beating returns and grow your wealth is to make long-term investments in high quality companies with strong business models and positive outlooks.

With that in mind, I have picked out two top ASX 200 shares that I think would be great buy and hold investments:

a2 Milk Company Ltd (ASX: A2M)

I think that a2 Milk Company would be a great buy and hold investment option. It is a rapidly growing a2 protein-only infant formula and fresh milk company. Cow’s milk will traditionally contain two main types of beta casein proteins, A2 protein and A1 protein. As you might guess from its name, a2 Milk Company’s milk comes only from cows selected to naturally produce the A2 protein type. It believes this protein is better for people who experience challenges drinking conventional cow’s milk.

This unique selling point has gone down well with consumers. It has also seemingly created sticky revenues, with consumers reluctant to switch products lest they upset their stomachs. I believe this bodes well for its future growth and expect further market share gains in China and its expanding distribution footprint in North America to drive strong earnings growth over the next decade. This could mean the a2 Milk share price still has plenty of upside over the coming years. In addition to this, there is speculation that the company may soon put its sizeable cash balance to work with new product launches or acquisitions.

Cochlear Limited (ASX: COH)

Another ASX 200 share that I think investors ought to consider buying and holding is Cochlear. I’m a big fan of the hearing solutions company and believe it has a very positive long term outlook. This is thanks to the quality of its products, its sizeable market opportunity, and its high level of investment in research and development.

I think the latter will be key to keeping its products at the front of the pack and growing its market share in the future. And in respect to its market opportunity. The company estimates that less than 10% of people who would benefit from an implantable hearing solution are treated. I feel this gives the company a long runway for growth in the coming years and could be the catalyst to driving the Cochlear share price notably higher over the 2020s.

More reading

• Should you buy ASX gold shares like Saracen Minerals in July?
• Top brokers name 3 ASX 200 shares to sell right now
• ASX 200 up 0.9%: Citi lifts Afterpay price target, Webjet boosts liquidity
• Fund managers have been snapping up Sonic and these ASX 200 stocks
• Down 32% in FY20, is the NAB share price a buy this year?

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia owns shares of A2 Milk. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why I would buy and hold a2 Milk and this ASX 200 share until 2030 appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2BY8kNz

The Sensera Ltd (ASX: SE1) share price is charging 37% higher today on the back of its trading update.

It’s a leading end-to-end senor and wireless communications company in the internet of things (IoT) space. The sensors use wireless networks to provide customers with critical information.

Trading update highlights

In an ASX announcement released today, the group saw Q4 revenue of US$2.3 million resulting in FY20 revenue of US$11.7 million. This represented year-on-year (YOY) growth of 15%.

Pleasingly, the cash position of Sensera also improved in Q4 from US$0.3 million to US$1.3 million. 

Its COVID-19 sensor is expected to be deployed in significant volumes in FY21 with early orders of US$2 million. 

Sensera is expecting continued growth in gross margins in the second half of FY20. In a further positive development, gross margin performance for FY20 will attain 48% in comparison to 41% in FY19.

The group says the product mix shift, manufacturing changes and model changes have had the planned impact of improving margins and the last 2 quarters delivered gross margins of the 60% target model. 

Products – IOTS and MD

Internet of things solutions (IOTS)

Despite a slowdown in mining and manufacturing, the group shipped products to an additional 8 customers. 

Revenues have remained resilient and pleasingly, progress has been supported by recent design wins. 

Both the US military application with Triton Systems Inc, announced last month, and the European rail safety project have made progress. The company will likely see a material revenue increase in FY21 as a result of the partnerships.

MicroDevices (MD)

MicroDevices has continued growth with FY20 revenues totalling US$4.7 million. The Woburn, Massachusettes facility is an essential service through the medical markets the group serves and, therefore, continued operating over recent months.

The biggest impact for the MD business was an application made for one of the sensors used to detect COVID-19. Over US$2 million worth of orders has been obtained over the past 2 months. However, these sensors are still in pre-production and full production is expected in FY21. 

Outlook 

Management believes it is building a sustainable business through a cost reduction focus to increase margins. In addition, the group has been able to move multiple customer opportunities to FY21. The Sensera share price currently sits at 3 cents and it will be interesting to see where it goes after the company releases a detailed update at the end of July. 

More reading

• 2 exciting small cap ASX shares that could be destined for big futures
• Should you buy ASX gold shares like Saracen Minerals in July?
• Why I would buy and hold a2 Milk and this ASX 200 share until 2030
• Afterpay share price hits $67! Are BNPL shares in a bubble?
• Lendlease share price jumps 6% after being given conviction buy rating

Motley Fool contributor Matthew Donald has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the Sensera share price is up 37% today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3dSP0OI

We’ve had news today that WAAAX high-flyer, buy now, pay later (BNPL) pioneer and ASX growth market darling Afterpay Ltd (ASX: APT) has hit yet another record high. The Afterpay share price started trading today at $64.20 before reaching a new high of $67.34 (at the time of writing). It’s now up nearly 130% year to date and around 740% off the lows we saw in March. Holy Macaroni!

The Afterpay share price isn’t alone

It’s not just Afterpay that has been exploding in value in recent weeks. The entire BNPL sector has been on a tear. It seems to me (much like the dot-com bubble of the early 2000s) that all a company needs to do to attract a frenzy of investors is to have the word ‘pay’ in its company name or modus operandi.

Let’s look at Zip Co Ltd (ASX: Z1P). Zip shares are up ~62% year to date and up 448% from their March lows.

Openpay Group Ltd (ASX: OPY)? Up nearly 85% year to date and 622% since March.

How about Splitit Ltd (ASX: SPT)? It’s up 90.9% year to date and over 500% since its March lows

Pushpay Holdings Ltd (ASX: PPH)? Up 126% year to date and 269% since March.

Sezzle Inc (ASX: SZL) is up 157% year to date and more than 1,000% since March. Yowza!

You get the idea…

Are we in BNPL bubble territory?

Whenever I see numbers like these, I’ll be honest and tell you that alarm bells ring for me. I can’t conceivably accept that the real value of all these companies has doubled, tripled or more since March. Sure, the market may have tilted in the BNPL sector’s favour with shifts to online shopping and ‘cash flow management’ of purchases as a result of the coronavirus pandemic. But these numbers are bordering on ridiculous for me.

And apparently, I’m not the only one. According to reporting in the Australian Financial Review (AFR) yesterday, fund manager Investors Mutual is also shunning the BNPL sector. The AFR quotes Investors Mutual senior portfolio manager Simon Conn:

“We’ve seen an increased level of retail activity in the market and there’s not a lot of fundamental analysis going on but a lot of momentum. The small-cap market is particularly prone to fads and bubbles. You remember the dotcom boom, with stocks trading in excess of $1 billion with no profits and then falling apart.”

Mr Conn references the Afterpay share price as well as those of Zip, Splitit, Sezzle and Openpay. He points out that, together, these companies have combined market capitalisations of over $20 billion, but not a dollar of profits between them. “There’s very extreme valuations and a lot of risk in that sector,” said Mr Conn.

It’s hard to argue with cold, raw data like that.

Foolish takeaway

I think there is a lot of potential in the payments and buy now, pay later sector to be sure. We’re moving towards a cashless society and these kinds of companies stand to benefit the most. But right now, there’s no way I could regard the Afterpay share price, or any of the companies discussed above, as ‘fairly valued’. I do think the market is getting a little bubbly and carried away with these shares, and I’ll be sitting on the sidelines until things return to some semblance of rationality.

More reading

• Why the Afterpay share price zoomed to a new record high today
• Why Afterpay, Bigtincan, Dicker Data, & NIB shares are racing higher
• ASX 200 up 0.9%: Citi lifts Afterpay price target, Webjet boosts liquidity
• What’s next for WAAAX shares?
• Can the Afterpay share price climb another 150% in FY21?

Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of PUSHPAY FPO NZX and ZIPCOLTD FPO. The Motley Fool Australia owns shares of AFTERPAY T FPO. The Motley Fool Australia has recommended PUSHPAY FPO NZX and Sezzle Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Afterpay share price hits $67! Are BNPL shares in a bubble? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2YQV6Lv

The Lendlease Group (ASX: LLC) share price has been among the best performers on the S&P/ASX 200 Index (ASX: XJO) on Thursday.

In afternoon trade the international property and infrastructure company’s shares are up over 6% to $12.99.

Why is the Lendlease share price jumping higher today?

Investors have been buying Lendlease’s shares on Thursday after analysts at Goldman Sachs retained their conviction buy rating on them.

Although the broker acknowledges that its FY 2020 net profit after tax is going to fall well short of consensus expectations, it believes it is worth sticking with the company.

Its analysts expect the company’s profits to rebound strongly in FY 2021 and notes that its shares were changing hands at just 10.6x FY 2021 earnings prior to today’s gains.

In light of this, it has put a $16.55 price target on Lendlease’s shares, which implies further upside of 27% over the next 12 months.

Commenting on the new financial year, Goldman said: “LLC has executed agreements to sell a 25% stake in the first tower of One Sydney Harbour to Mitsubishi Estate, locking in a A$100m post-tax gain for FY21 and reducing its future funding requirements for the A$2bn project. The Group also confirmed that PSP Investments has signed on as LLC’s partner for the A$4bn Milano Santa Giulia project.”

“More broadly, management noted continued strong demand from capital partners for new opportunities and highlighted Melbourne Quarter (Commercial), the Google Bay Area project, 30 Van Ness (San Francisco), International Quarter London, Silvertown Quays and Milan Innovation District as likely drivers of near-term development origination profits,” it added.

The broker is also pleased to see that the exit of its Engineering business is on track to complete in the near future.

Its analysts said: “Management confirmed again today that LLC expects the sale of the Engineering business to complete early this financial year. In our view, LLC’s decision to bring all remaining estimated exit costs to account in FY20 increase the likelihood that completion of the sale is imminent.”

Should you invest?

I agree with Goldman Sachs on Lendlease and see a lot of value in its shares. Especially, now the bad news is out of the way.

Furthermore, I think it could be top option if you’re an income investor. Goldman Sachs estimates that Lendlease’s shares currently offer a FY 2021 dividend yield of 4.4%.

More reading

• Australian businesses are running out of cash

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Lendlease share price jumps 6% after being given conviction buy rating appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2YSubyE

Medical technology is a broad field covering areas like biotechnology, pharmaceuticals, and information technology. Advancements in medical technology improve the way doctors diagnose and treat patients, leading to better health outcomes. The global medical technology industry is worth some US$430 billion and growing. I believe the below 3 ASX medical technology companies have promising futures in the sector.

Pro Medicus Limited (ASX: PME)

Pro Medicus provides imaging software to hospitals, diagnostic imaging groups and healthcare entities. The company currently operates across Australia, Europe and the United States. Its solutions provide medical accounting, clinical reporting, appointment scheduling, and management information applications. The Pro Medicus share price has largely recovered from the March market correction and is trading at $26.57. This is back on par with levels seen in early 2020. Pro Medicus recently signed a $22 million deal with Chicago-based Northwestern Memorial HealthCare which will implement its Visage 7 technology.

MedAdvisor Ltd (ASX: MDR)

MedAdvisor is behind an innovative software that puts a virtual pharmacist on customer smartphones, tablets, and PCs. The software reminds users when to take medications, fill recurring scripts, and even manage the medication of other family members. It connects with local pharmacies, allowing customers to order prescriptions from their phones for collection. The MedAdvisor share price is up 86% from its March low, currently trading at 54 cents. This week MedAdvisor announced a strategic alliance with NASDAQ-listed HMS Holdings Corp  (NASDAQ: HMSY) under which MedAdvisor will integrate with HMS’ health engagement platform. This will enable healthcare organisations to proactively communicate with patients, with MedAdvisor to generate revenue from each digital message sent on behalf of HMS’ clients.  

Respiri Ltd (ASX: RSH)

Respiri produces medical devices designed to monitor asthma symptoms for use in hospitals and at home. A respiratory eHealth software-as-a-service (SaaS) company, Respiri is seeking to improve the management of asthma, which impacts some 340 million people worldwide. The Respiri share price has increased by 60% to 9 cents a share from a low of 6 cents in May. Last week Respiri announced an agreement with the University of Edinburgh to partner on a new data research centre. The centre will use data collected using Respiri devices to develop innovations in the delivery of care for people with asthma, chronic obstructive pulmonary disease, and respiratory infections. The ASX medical technology company plans to enter the European market in 2021 following its Australian commercial launch in the fourth quarter of the calendar year 2020.

More reading

• Where to invest $5,000 into ASX shares in July
• Could one of these ASX shares be ‘the next Afterpay’?
• 3 ASX growth shares to buy with $3,000
• 3 exciting small cap ASX healthcare shares to watch
• ASX 200 jumps almost 4%, Webjet share price soars

Kate O’Brien has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of MedAdvisor. The Motley Fool Australia has recommended MedAdvisor and Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Add these 3 ASX medical technology companies to your watch list appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2ZsmkqW

The Todd River Resources Ltd (ASX: TRT) share price has risen by 50% to $0.039 since it came out of a trading halt on Wednesday. This follows an announcement on Wednesday morning related to an acquisition that the company labelled as “highly prospective”.

What did Todd River Resources announce?

Todd River Resources announced on Wednesday that it had entered an agreement to acquire 100% of 2 private companies – Marlee Base Metals Pty Ltd and Moonknight Pty Ltd. Following the acquisitions, the company will hold a 270km² land position in the South West Yilgarn Craton, Western Australia.

According to the announcement, this land has numerous nickel-copper bodies over more than 40km of strike extent. The key project area is the Berkshire Valley Project, which is located 100km north of a recent discovery of nickel, copper and platinum at Julimar by Chalice Gold Mines Limited (ASX: CHN).

One of the acquisitions also includes the ownership of 3 additional nickel, cobalt and copper targets in Western Australia. 

The company will pay cash of $100,000 for the acquisitions along with scrip of 100,000,001 Todd River Resources shares. A director from one of the companies acquired, Ian Murray, also the former managing director of Gold Road Resources Ltd (ASX: GOR), will join the Todd River Resources board.

The transaction will be subject to shareholder approval at an extraordinary general meeting. If the transaction is approved, the company plans to start exploration immediately.

How has Todd River Resources performed recently?

Todd River Resources is an exploration company that holds a portfolio of base metals and gold exploration assets in Australia.

According to the company’s most recent quarterly report, Todd River Resources ended the quarter with $1.55 million in cash (as at 31 March 2020). In that quarter, the company completed design of geological programs that were ready to be implemented at its Nanutarra Nickel and Mt Hardy projects. Additionally, while there had been some delay in exploration at Mt Hardy due to travel restrictions, an aircore drilling program to test extension of a known anomalism had been designed and was planned to be commenced in the third quarter. 

Due to the economic impacts of the coronavirus, directors of the company saw a 40% pay cut for the final quarter of the 2020 financial year. The company predicted that spending would be subdued for the next 2 quarters, but that it would recommence exploration activities at the earliest opportunity. 

About the Todd River Resources share price

At the time of writing, Todd River Resources shares are up 387.5% from their 52-week low of $0.008 cents. The Todd River Resources share price has returned 95% since the beginning of the year, but is down by 2.5% since this time last year. 

More reading

• Why the Afterpay share price zoomed to a new record high today
• Is the Vanguard Property ETF a good long-term investment?
• Osteopore share price storms 270% higher on distribution deal
• Is the Oil Search share price worth buying?
• Temple & Webster share price at an all-time high after capital raise

Motley Fool contributor Chris Chitty has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Todd River Resources share price up 50% in 2 days after acquisition news appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3eYvtOA

The Afterpay Ltd (ASX: APT) share price has been a very impressive performer once again on Thursday.

This afternoon the payments company’s shares have charged 7.5% higher and reached a new record high of $66.97.

Why is the Afterpay share price at a new record high?

Investors have been buying the company’s shares again on Thursday after it was the subject of a positive broker note out of Citi.

Although the broker has retained its neutral rating on the buy now pay later platform provider’s shares, it has more than doubled its price target on them.

Citi has lifted its price target to $64.25 from $27.10 after upgrading its earnings estimates materially. This follows its impressive growth in the UK and United States and its belief that Afterpay will benefit from the acceleration in the shift to online shopping.

Costa retains its buy rating.

Afterpay isn’t the only company that Citi has given a boost to on Thursday.

The Costa Group Holdings Ltd (ASX: CGC) share price is up 7% this afternoon after the broker retained its buy rating and $3.40 price target on the horticulture company’s shares.

The broker notes that wholesale prices of many key products were very strong in Australia in June. It also points out that global citrus pricing trends have been favourable recently.

Whitehaven upgraded.

And finally, the Whitehaven Coal Ltd (ASX: WHC) share price is up over 5% at the time of writing. This could also have been driven by a broker note out of Citi.

On Wednesday the broker upgraded the coal miner’s shares to a buy rating from neutral with a $1.75 price target. It feels that thermal coal prices have dropped to a level that will lead to some producers curtailing production in an effort to boost prices.

More reading

• Why Afterpay, Bigtincan, Dicker Data, & NIB shares are racing higher
• ASX 200 up 0.9%: Citi lifts Afterpay price target, Webjet boosts liquidity
• What’s next for WAAAX shares?
• Can the Afterpay share price climb another 150% in FY21?
• 10 FY21 ASX share picks revealed by Bell Potter

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended COSTA GRP FPO. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the Afterpay share price zoomed to a new record high today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/38iL7lj

Should investors looking for ASX dividend income consider Vanguard Australian Property Securities Index ETF (ASX: VAP) in 2020?

This exchange-traded fund (ETF) from the reputable Vanguard Group invests in ASX-listed real estate investment trusts (REITs), using the S&P/ASX 300 A-REIT index as a benchmark.

REITs are companies that have the majority of their assets invested in land, property, and housing assets, of which they receive a rental income. For a REIT, 90% or more of this rental income is usually required to be distributed every year to their investors, without tax paid at the corporate level. This unique system translates into a good chance that a top-quality REIT will offer a generous trailing distribution yield — albeit without the benefits of franking credits (as no company tax has been paid). This inherently makes REITs a popular choice for income investors.

Which ASX REITs does VAP hold?

At the time of writing, this Vanguard ETF holds 30 ASX REITs. The 5 largest holdings are as follows:

1. Goodman Group (ASX: GMG) with a 23.55% weighting
2. Scentre Group (ASX: SCG) with an 11.34% weighting
3. Dexus Property Group (ASX: DXS) with a 9.32% weighting
4. Mirvac Group (ASX: MGR) with an 8.89% weighting
5. Stockland Corporation Ltd (ASX: SGP) with an 8.31% weighting

Some more prominent holdings you might have come across include National Storage REIT (ASX: NSR), BWP Trust (ASX: BWP), Rural Funds Group (ASX: RFF) and Unibail-Rodamco-Westfield (ASX: URW).

As a whole, the ETF’s median market capitalisation is $9.24 billion. Its average price-to-earnings (P/E) ratio comes in at 11.09 and the trailing dividend yield at 5.86%.

Is VAP a good investment for income?

With a trailing dividend/distribution yield of 5.86%, on the surface, VAP looks to be a top ASX share to own for dividend income. With interest rates at record lows, achieving a near-6% yield on investment sounds like a pretty good deal. However, this trailing yield may not be reflecting the current commercial environment for the REIT sector. Many of VAP’s holdings operate in the retail sector. Scentre Group, as an example, owns the Westfield-branded chain of shopping centres in Australia and New Zealand. Retail shops are still emerging from one of the most disruptive and damaging times in the history of Aussie retail. Many shopping centres would have been almost completely closed over the March and April months. This would have led to foregone rental payments to landlords like Scentre. In turn, this places enormous pressure on the REITs’ abilities to pay dividends at all.

Most ASX REITs haven’t yet told the market what their intentions regarding dividend payments are for the rest of 2020. But I’m expecting, at the very least, a significant dip for investors.

Going beyond 2020, I would expect things to get somewhat rosier. But we have to consider that the retailing landscape may have changed forever as a result of the coronavirus pandemic. As such, I think a better strategy is to find your favourite REITs within this ETF and invest in those separately, rather than buying this comprehensive index fund.

More reading

• The impact of housing figures on real estate shares
• Replace your term deposits with these ASX dividend shares
• Amazon defends new Sydney warehouse as ’employment creator’
• 10 FY21 ASX share picks revealed by Bell Potter
• These ASX 200 shares were the worst performers of FY20

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended RURALFUNDS STAPLED. The Motley Fool Australia has recommended Scentre Group. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Is the Vanguard Property ETF a good long-term investment? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/38vmUbD

The Osteopore Ltd (ASX: OSX) share price rocketed as much as 270% higher at one point today, after the company announced it has signed a distribution agreement that opens up the potentially lucrative US market.

Why is the Osteopore share price surging?

Earlier this morning, Osteopore announced that the company has signed a non-exclusive, 2-year agreement with established US market leader Bioplate Inc. The agreement will see Bioplate help Osteopore sell its patented 3D printed, bioresorbable products for cranial and neurosurgery procedures. The distribution agreement covers 6 states in the US market and Bioplate will cover all technical support requirements for Osteopore’s products.

The agreement with Bioplate is Osteopore’s first distribution agreement since the company’s IPO in 2019. Bioplate has over 20 years of experience in providing cranial fixation solutions and will provide Osteopore with an established network of health professionals, hospitals and health services in the US.

According to Osteopore, the graft substitute market is worth around US$4 billion, with sales of permanent implants estimated at over US$100 million annually. Osteopore believes that penetrating the US market is a key strategic objective, with US demand accounting for a large portion of the global demand.

What does Osteopore do?

Osteopore is an Australian and Singapore-based medical technology company that has commercialised a range of patented, 3D printed bioresorbable products. These 3D printed implants act as a scaffold for bone growth and can be used across various surgeries. As opposed to traditional bone grafts, Osteopore’s implants naturally dissolve over time, leaving only health bone tissue.

According to Osteopore, the company’s protective implants can reduce post-surgery complications by reducing the risk of secondary infections. All 3 of Osteopore’s products (Osteoplug, Osteomesh and Osteostrip) have received FDA approval in the US and are being sold to hospitals around the globe.

Earlier this year, Osteopore reported a 60% increase in revenue for the quarter ending March 2020. The company generated $321,00 in revenue for the quarter whilst also receiving approval from the Australian Therapeutic Goods Administration for several of its craniofacial products.

Foolish takeaway

Following a pause in trading mid-morning, shares in Osteopore resumed trading and are up more than 150% at the time of writing. The Osteopore share price hit an intra-day high of $1.49 earlier, representing a gain of more than 270% for the day.

More reading

• Is the Oil Search share price worth buying?
• Temple & Webster share price at an all-time high after capital raise
• Top brokers name 3 ASX 200 shares to sell right now
• Why the Kathmandu share price is up 11% today
• Why Afterpay, Bigtincan, Dicker Data, & NIB shares are racing higher

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Osteopore share price storms 270% higher on distribution deal appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2VEMA01